Tianjiao Wang

Company: Adaptimmune Therapeutics plc.

Job title: Associate Director, Biomarker and CDx Science & Operations

Seminars:

Panel Discussion: What challenges occurred during the co-development of the therapy with the companion diagnostic? 6:50 pm

• Challenges to align timelines of clinical program and CDx program (fast transition from phase 1 study to registrations study, orphan drug designation with accelerated approval, etc.) • Difficulty of sample procurement in the context of rare disease • How does this launch impact the patients with synovial sarcoma? • What are some of the…Read more

day: Agilent